Effects of administration of an anti-CD5 plus immunoconjugate in rheumatoid arthritis. Results of two phase II studies. The CD5 Plus Rheumatoid Arthritis Investigators Group

Autor:	V, Strand, P E, Lipsky, G W, Cannon, L H, Calabrese, C, Wiesenhutter, S B, Cohen, N J, Olsen, M L, Lee, T J, Lorenz, B, Nelson
Rok vydání:	1993
Předmět:	Adult Male Dose-Response Relationship Drug Immunotoxins T-Lymphocytes Antibodies Monoclonal Cell Count Ricin Middle Aged CD5 Antigens Arthritis Rheumatoid Methotrexate Treatment Outcome Antigens CD Azathioprine Humans Drug Therapy Combination Female Prospective Studies Aged
Zdroj:	Arthritis and rheumatism. 36(5)
ISSN:	0004-3591
Popis:	To evaluate the safety and activity of an immunoconjugate of ricin A chain and anti-CD5 monoclonal antibody (anti-CD5 IC), with and without concomitant methotrexate and/or azathioprine, in the treatment of rheumatoid arthritis (RA).Seventy-nine patients with active RA were enrolled in 2 prospective open-label protocols.Using composite criteria, response rates were 50-68% at 1 month and 22-25% at 6 months. Transient depletion of CD3/CD5 T cells was observed on days 2 and 5 of treatment, with reconstitution on day 15 or day 29. Treatment-associated adverse effects were common but resolved rapidly without sequelae.These findings suggest activity of anti-CD5 IC in active RA and warrant confirmation in a multicenter randomized study (currently underway).
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::9816eaf6413ee7c9612b69cfa2116635 https://pubmed.ncbi.nlm.nih.gov/7683881 Zobrazit plný text záznamu Plný text